NCT05300386View on ClinicalTrials.gov

Wearable Devices to Assess Effects of Central Nervous Medications on Physical Conditions in Patients With Sleep Problems

CompletedOBSERVATIONAL
Enrollment

52

Participants

Timeline

Start Date

May 30, 2018

Primary Completion Date

May 29, 2021

Study Completion Date

January 31, 2022

Conditions
Anxiety DisordersSleep Apnea
Interventions
DRUG

Escitalopram

We use Escitalopram 5\~10 mg for two groups to observe the impact of sleep apnea on the treatment of generalized anxiety disorder

Trial Locations (1)

114

Tri-Service General Hospital, Taipei

All Listed Sponsors
lead

Tri-Service General Hospital

OTHER

NCT05300386 - Wearable Devices to Assess Effects of Central Nervous Medications on Physical Conditions in Patients With Sleep Problems | Biotech Hunter | Biotech Hunter